Current awareness: Pharmacoepidemiology and drug safety.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 699, doi. 10.1002/pds.933
- Publication type:
- Article
Works in Pharmacoepidemiology & Drug Safety, 2003, Vol 12, Issue 8
Results: 9
1
2
Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey(No conflict of interest was declared.).
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 663, doi. 10.1002/pds.884
- By:
- Publication type:
- Article
3
A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort(No conflict of interest was declared.).
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 669, doi. 10.1002/pds.878
- By:
- Publication type:
- Article
4
Adverse drug reactions in a South Indian hospitaltheir severity and cost involved(No conflict of interest was declared.).
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 687, doi. 10.1002/pds.871
- By:
- Publication type:
- Article
5
Risk assessment of drugs, biologics and therapeutic devices: present and future issues(As Workshop chair, Dr Strom takes responsibility for the content of this article.).
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 653
- By:
- Publication type:
- Article
6
Psychotropic drugs and fatal pulmonary embolism.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 647, doi. 10.1002/pds.841
- By:
- Publication type:
- Article
7
Patient approach and experience regarding complementary medicine: survey among hospitalized patients in a university hospital.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 679, doi. 10.1002/pds.840
- By:
- Publication type:
- Article
8
Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment(The views expressed in this article are those of the authors and do not necessarily represent the views or policies of the Food and Drug Administration or the US Environmental Protection Agency.)
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 633, doi. 10.1002/pds.796
- By:
- Publication type:
- Article
9
Benefit-risk analysis: examples using quantitative methods.
- Published in:
- Pharmacoepidemiology & Drug Safety, 2003, v. 12, n. 8, p. 693, doi. 10.1002/pds.794
- By:
- Publication type:
- Article